Biotech Values

[GrthzGd]

Overall [ECYT] looks like an impressive deal and, based on the terms, a better deal than the one THLD signed with Merck KGaA.

My impression from the transcript, and from the deal itself, is that Endocyte managed to get quite a bidding war going among Big Pharma, resulting in: a nice chunck of cash, solid milestones, a royalty, much of ECYT's technology remaining in the kitty, a marketing partner. What's not to like? Also, the price previously hovered above 11 anyway. Yrs truly sold out yesterday, then cravenly bought back in. So far, no regrets.